Market Cap 34.12M
Revenue (ttm) 0.00
Net Income (ttm) -62.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 41,000
Avg Vol 37,924
Day's Range N/A - N/A
Shares Out 22.15M
Stochastic %K 14%
Beta 1.30
Analysts Strong Sell
Price Target $7.00

Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The com...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 802 1989
Address:
12407 N. Mopac Expy., Suite 250 #390, Austin, United States
PenkeTrading
PenkeTrading Jun. 24 at 5:18 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Rein Therapeutics Inc. Is that bullish or bearish? $RNTX #Rein #RsiOversold #NASDAQ
0 · Reply
Klinsmann
Klinsmann Jun. 3 at 4:20 PM
$RNTX starter
0 · Reply
BlackPillOverdose
BlackPillOverdose May. 29 at 3:01 PM
$RNTX why no
0 · Reply
Latest News on RNTX
US FDA puts on hold Rein Therapeutics' lung disease drug trial

Jun 12, 2025, 5:18 PM EDT - 14 days ago

US FDA puts on hold Rein Therapeutics' lung disease drug trial


PenkeTrading
PenkeTrading Jun. 24 at 5:18 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Rein Therapeutics Inc. Is that bullish or bearish? $RNTX #Rein #RsiOversold #NASDAQ
0 · Reply
Klinsmann
Klinsmann Jun. 3 at 4:20 PM
$RNTX starter
0 · Reply
BlackPillOverdose
BlackPillOverdose May. 29 at 3:01 PM
$RNTX why no
0 · Reply